Genomics May Improve Diagnosis of Neurodevelopmental Disorders in Italy

Why It Matters

Providing molecular diagnoses transforms care pathways for affected children and informs family planning, while the novel gene findings broaden therapeutic targets and research priorities across Europe.

Key Takeaways

• 29 families received genetic diagnoses via whole-genome sequencing
• Study analyzed 110 children and parents, generating ~26 million variants
• AI algorithms pinpointed known and novel neurodevelopmental disorder genes
• KALRN mutation identified, expanding the gene list for autism research

Pulse Analysis

Neurodevelopmental disorders, affecting roughly 1 % of Italian children aged 7‑9, present a diagnostic challenge due to heterogeneous symptoms. Traditional clinical assessments often leave families without clear etiologies, limiting personalized interventions. Genomic technologies, especially whole‑genome sequencing, have emerged as powerful tools to uncover hidden genetic contributors, offering a pathway toward precision medicine in pediatrics.

The Italian Institute of Technology partnered with the regional health authority to sequence 110 affected children and their parents, producing an unprecedented dataset of about 26 million variants. Leveraging artificial‑intelligence pipelines, researchers filtered this massive pool to identify pathogenic mutations, achieving a 26 % diagnostic yield—29 families received definitive genetic explanations for their conditions. The study’s design, encompassing autism‑only, intellectual disability, and combined phenotypes, ensures findings are representative of the broader neurodevelopmental spectrum.

Beyond immediate clinical impact, the discovery of a KALRN mutation and other previously unlinked genes signals a shift in the scientific understanding of autism and related disorders. These insights will prompt re‑evaluation of unsolved cases nationwide and stimulate targeted drug development. For Italy’s healthcare system, integrating genomics into routine pediatric care could reduce long‑term costs by streamlining diagnostics and enabling early, tailored therapies, positioning the country as a leader in European genomic medicine.